The decision taken by research ethics committees (RECs) while assessing pharmacogenetic (PGx) substudies as part of international clinical trials is almost unknown. A total of 255 applications of 36 PGx substudies embedded in clinical trials (12 phase 2, 24 phase 3) were submitted to 72 RECs in 2006-2007 by GlaxoSmithKline in Spain. These were trials of 17 different compounds, aimed to be conducted in the five continents. Of the 255 applications, 226 (89%) were directly approved by RECs without raising any queries to the sponsor; 1% (3/255) were plainly rejected by two RECs. The rest (10%) were followed by 64 queries asked by 16 RECs on 25 PGx substudies. Following responses from the sponsor, all but two applications were approved. Thus, the RECs involved finally approved 98% (250/255) of the submitted applications. The requirements specifically raised by two RECs (PGx samples to be transferred to a public biobank or alternatively destroyed immediately, or storage permitted only 5 years after the trial is concluded) could not be met by the sponsor. It can be inferred from the results obtained that ethical and scientific standards implemented by the sponsor in the design, conduct and sample management of PGx substudies satisfied the vast majority (70/72; 97%) of RECs involved in this study.
Introduction
Pharmacogenetic (PGx) studies have been increasingly incorporated into clinical trials as a key part of the development of new compounds. In fact, it has been recommended that in drug development, trials sponsored by both the private and public sectors, should make provision for PGx testing. 1, 2 So far, clinical applications of PGx have been notable but not very many. 3 Thus, PGx has proven to be useful in addressing, for instance, safety issues when applied to several drugs that have been in the market for years. 4 Both the European and US regulatory agencies [5] [6] [7] [8] and international organizations 9 or boards 2 have issued guidelines or reports on this subject.
The vast majority of PGx studies are, in fact, substudies embedded in clinical trials. This is why a given PGx substudy is usually assessed by research ethics committees (RECs; equivalent to Institutional Review Boards in the United States) at the same time the clinical trial is reviewed. However, it is worth mentioning that a PGx substudy has its own protocol requirements and patient information sheet/informed consent document, different from those of the clinical trial. Furthermore, PGx studies presents specific challenges from the legal, ethical and scientific perspectives that have to be addressed by the RECs. [10] [11] [12] [13] That is why, on some occasions, RECs approve the clinical trial while rejecting the approval of the PGx substudy. This paper describes the decision made by Spanish RECs regarding the assessment of PGx substudies in the clinical development of new drugs.
Results
All (n ¼ 36) clinical trials were approved by both the RECs involved and the Spanish Medicines Agency. Table 1 shows the assessment outcome of the PGx substudies applications. Most (226/255; 89%) PGx substudies were approved by RECs without any query being raised.
Sixty-four queries belonging to 25 PGx substudies were raised by 16 different RECs. Of these, three were regional RECs and the rest were local (institution based); each REC issued a number of queries concerning 1-5 different PGx substudies. Table 2 lists the number of queries per category. Following response to the 64 queries, all applications except two were approved. These two cases led to eventually rejection of the PGx substudy because of the sponsor's inability to comply with the storing and sample destruction requirements made by the two RECs. This contrasts with the approval granted by some 58 other RECs involved in these studies. Particularly, one of the substudies rejected was embedded in a large oncology phase 3 trial otherwise approved by 6 regional and 24 local RECs throughout Spain.
One regional REC requested the sponsor that, after conclusion of the trial, all samples be forwarded to a public biobank or, conversely, if this was not acceptable, to destroy them. Another REC, affiliated to a University Hospital, asked the sponsor to retain PGx samples only for 5 years after the study end. As both requirements could not be met by the sponsor, RECs were informed accordingly and they finally rejected the conduct of PGx sampling at their sites. Additionally, these two RECs directly rejected 3 applications (3/255, 1%) of 3 PGx substudies with no further reason stated for this decision.
In summary, only 5 (5/255, 2%) applications of 5 different PGx substudies were eventually not approved by only 2 (2/ 72, 3%) RECs.
Discussion
Spanish regulations on clinical trials and PGx substudies mandate obtaining the approval of both RECs and Spanish Medicines Agency before their initiation. The European regulations 14 state that for international multicentre trials just one REC per member state should issue a single opinion. However, the current Spanish clinical trial (and PGx) protocol review system allows all RECs involved in multicentre trials to assess and eventually decide if the trial (or the PGx substudy) will be conducted in the centre(s) under their supervision. This particular situation of Spain within the European Union offers a unique opportunity for analysing the outcome of RECs decisions regarding PGx substudies. Whereas in countries such as Belgium, France, Italy, The Netherlands or the United Kingdom, the 36 PGx substudies (and their corresponding clinical trials) meant that 36 responses would have been issued by the RECs, in Spain this same number of protocols turned out to need 255 applications, each of which could have been followed by queries regarding any aspect of the PGx substudy from each of the 72 RECs involved.
In our country, one REC per multicentre clinical trial chosen by the sponsor, acts as the so-called 'Lead REC', and takes responsibility for collecting the queries and suggestions raised by the other RECs involved in the same trial. The list of all queries is then forwarded by the Lead REC to the sponsor and shared among all RECs involved in study. After receiving the answers from the sponsor, the Lead REC issues a final (single) decision regarding both the clinical trial and the PGx substudy. However, even if the final decision of the Lead REC Assessment of pharmacogenetic substudies by RECs is a positive one, a REC could still disagree on this and decide that, for instance, the PGx substudy will not be conducted in the centres affiliated with it.
Although there is plenty of information from different countries on how RECs deal with assessing clinical trial protocols, [15] [16] [17] [18] [19] [20] there are very few data on the process and final decision taken by RECs regarding PGx studies. 21 Arledge et al. 21 reported in the late 1990s, that among those investigators accepting to implement a PGx amendment at their clinical trial sites (only 72% of the total), very few of the RECs (2%) involved from various countries did not approve it, mentioning having concerns on inadequate background for evaluating the research, lack of scientific rationale and concerns about patient confidentiality. Our results showed that almost all Spanish RECs trust the sponsor on the design, conduct and sample management of PGx substudies, since 98% of all applications resulted in their approval. Moreover, and supporting this view, 89% of PGx applications were directly approved after the first review took place without any query being raised.
Conversely, the number of PGx substudies rejected was very low, and limited to only two RECs. As indicated above, the conditions set for approval by these two RECs were not acceptable by the sponsor, because in practice it would make the samples difficult to retrieve or they might be precociously destroyed, before their likely use. Without questioning the duty of any REC to safeguard the safety, rights and well-being of study participants 22, 23 by requesting from the sponsor any appropriate measure suitable for their local conditions, imposing important limitations on sample storage or time to destruction can hardly be considered to achieve these objectives. Furthermore, ethical concerns may be raised if the provisions for time (and adequacy) of PGx sample storage are made so limited that the possibility of their future use is greatly diminished. There is no homogenously accepted time for PGx sample storage. Times range up to 25 years after the clinical trial conclusion. GSK stores PGx samples for 15 years as identifiable materials that are unidentified for research purposes, but can be linked to their sources through the use of a code.
What would be a reasonable PGx storage time? In the demonstration that a PGx test can be used to prevent the hypersensitivity reaction to abacavir in HIV-infected patients, 24 8 years of research were needed from the first clinical study to that confirming the clinical utility of HLA-B* 5701 screening. 25 In this example, one of the first studies initiated in 1999, required obtaining additional blood samples from patients included in previous trials, with a history of having developed (cases), or not (controls), a hypersensitivity reaction to abacavir. 26 In another example, more than 15 years elapsed since the description of P450 CYP2C9 as responsible for the metabolism of S-warfarin, 27 until the publication of the first prospective trial, in which the warfarin dose in patients randomized to the experimental arm was prescribed according to their CYP2C9 and VKORC1 genotypes (and clinical variables such as gender, age and weight). 28 Although the PGx data has been included in the US prescribing information of warfarin, the controversy on the clinical utility of genetic testing still remains. 29, 30 These examples show that storing PGx samples for periods of 15 years (or more), could be critical in avoiding the need for new prospective studies, that could even be unethical or technically impossible (for example, if the incidence of the adverse event is very low) to conduct, or at least, to avoid initiating new studies to obtain blood samples from patients that were included in previous trials. By avoiding these new studies, the time needed to provide clinicians with tools for a better use (in terms of safety or efficacy) of medicines would be reduced.
We can only speculate about the rationale behind the decision of the two RECs that did not approve the PGx substudies, but one could assume that they judged that not all applicable ethical and scientific standards were met. But, if this is the reason, why would these RECs be satisfied by the ability of the sponsor to fulfil these standards while the trial is conducted (or, even for 5 more years) but not for a longer period of time, say 15 years? The recently passed Biomedical Research Law 31 that encourages the conduct of PGx research in Spain, has addressed a number of issues, including the boundaries of informed consent and the appropriate collection, use, storage and destruction of biological samples. This new legislation may clarify matters and help these two RECs in revisiting their approaches with respect to the requirements mentioned above.
In summary, the results of this study show that the vast majority of RECs accept the ethical and scientific standards put in place by the pharmaceutical sponsor in the design, conduct and sample storage of PGx substudies. Exceptionally, however, two RECs asked for sample management requirements that could not be met by sponsors, and that, in practice, prevented conducting PGx studies in the centres affiliated with them. Greatly limiting the sample storage time seems inadequate by the few examples of successful use of PGx testing and it does not seem warranted, as corroborated by the decisions of the remaining 70 RECs involved in this study.
Materials and methods
This is a retrospective study conducted by reviewing the information contained in GlaxoSmithKline database of international multicentre clinical trials submitted to RECs in Spain in the years 2006 and 2007. A total of 36 different clinical trials with their respective PGx substudies, involving 255 individual applications to 72 different RECs, were analysed. These were phase 2 (n ¼ 12) and phase 3 (n ¼ 24) trials, to be conducted by 292 hospital-based investigators and in 2 primary care centres, as part of the clinical development plan of 17 drugs. These clinical trials encompassed the following disease areas (n, %): oncology (17, 47%), neurology (7, 19%) , rheumatology (6, 17%), HIV (4, 11%), urology (1, 3%) and psychiatry (1, 3%), and were placebo-controlled (n ¼ 20), vs active comparator (n ¼ 9) or non-comparative (n ¼ 7). The clinical trials (and PGx substudies) included in this study were aimed to be conducted in Asia, Australia, Europe, North and South America, and South Africa. The number of subjects to be recruited in each trial ranged from 33 to 8000.
The data extracted for this study included all information regarding the applications to all RECs included in the initial submission for each trial. Any subsequent submissions made to additional RECs, to increase the number of participating centres in the trial, were not included. This step was taken to prevent analysing data from RECs that reviewed a given study already knowing the outcome of the positive assessment of the PGx substudy by another REC (and even by the regulatory authority). The queries received from RECs were classified into the following categories: study design, data protection, samples, information to patients of study results and informed consent. The term 'query' refers to questions asked by RECs to the sponsor/investigator about any aspect of the submitted documentation (for example, PGx specific patient information sheet, the PGx substudy protocol requirements).
